Value
6.3/10data confidence 33%| Component | Sub-score |
|---|---|
| P/S | 4.5 |
| Analyst target | 7.5 |
BNTX · Why this verdict
Why BioNTech (BNTX) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score5.1/10
ConfidenceMEDIUM
MacroNEUTRAL
TrendMatrix Research · core thesis
Engine thesis — one sentence
BioNTech has 19.0% upside to the $104.93 analyst target and low leverage, but quality of 3.4 is below the 4.0 floor, the company burns cash and insiders have been selling.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
The $88.17 price is 19.0% below the $104.93 analyst target, with analyst upside of 32% and a reward-to-risk of 3.03. Upside pct | Price rises toward the $104.93 target over 12 months as pipeline progress is recognized. | →Stable |
| CounterBiotech targets are binary on trial results and are often revised sharply after a single readout. | ||
Quality is 3.4, below the 4.0 floor, with free cash flow at -9% of revenue and a Rule of 40 reading of -69 (fail). Quality breakdown | Cash burn narrows below 5% of revenue and the quality score returns above 4.0. | →Stable |
| CounterContinued cash burn without a commercial product offsetting it would erode the balance sheet. | ||
Insiders have sold $77,751,586 (0.351% of market cap), scored as notable selling. Insider breakdown | Insider selling slows to under 0.1% of market cap over the next 12 months. | ↑Improving |
| CounterLarge insider sales near a possible catalyst could signal reduced confidence in the pipeline. | ||
Momentum is 4.3/10, with the price below its 200-day average (slope flat) despite rising on-balance volume. Momentum breakdown | Price reclaims the 200-day average and momentum rises above 4.5. | ↑Improving |
| CounterA flat 200-day slope with the price below it shows no trend support; volume score is only 0.3. | ||
Debt-to-equity scores 9.9/10 and the current ratio scores 5.2, reflecting minimal leverage that gives runway to fund research. Components | Debt-to-equity score stays above 9 while cash burn stays small. | ↓Deteriorating |
| CounterA strong balance sheet does not protect against a failed pivotal trial, which is the core biotech risk. | ||
The $88.17 price is 19.0% below the $104.93 analyst target, with analyst upside of 32% and a reward-to-risk of 3.03.
→StableUpside pct
- Expectation
- Price rises toward the $104.93 target over 12 months as pipeline progress is recognized.
CounterBiotech targets are binary on trial results and are often revised sharply after a single readout.
Quality is 3.4, below the 4.0 floor, with free cash flow at -9% of revenue and a Rule of 40 reading of -69 (fail).
→StableQuality breakdown
- Expectation
- Cash burn narrows below 5% of revenue and the quality score returns above 4.0.
CounterContinued cash burn without a commercial product offsetting it would erode the balance sheet.
Insiders have sold $77,751,586 (0.351% of market cap), scored as notable selling.
↑ImprovingInsider breakdown
- Expectation
- Insider selling slows to under 0.1% of market cap over the next 12 months.
CounterLarge insider sales near a possible catalyst could signal reduced confidence in the pipeline.
Momentum is 4.3/10, with the price below its 200-day average (slope flat) despite rising on-balance volume.
↑ImprovingMomentum breakdown
- Expectation
- Price reclaims the 200-day average and momentum rises above 4.5.
CounterA flat 200-day slope with the price below it shows no trend support; volume score is only 0.3.
Debt-to-equity scores 9.9/10 and the current ratio scores 5.2, reflecting minimal leverage that gives runway to fund research.
↓DeterioratingComponents
- Expectation
- Debt-to-equity score stays above 9 while cash burn stays small.
CounterA strong balance sheet does not protect against a failed pivotal trial, which is the core biotech risk.
Per-dimension breakdown
Quality
3.4/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 0.0 |
| ROA | 0.0 |
| Gross margin | 10.0 |
| Net margin | 0.0 |
| Current ratio | 5.2 |
| FCF quality | 0.0 |
| Moat | 5.5 |
| Rule of 40 | 3.0 |
| Piotroski F | 6.7 |
- ▸Cash-burning: FCF -9% of revenue
- ▸Rule of 40: -69 (fail)
Growth
5.0/10data confidence 50%Momentum
3.9/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 4.5 |
| MACD | 9.2 |
| OBV | 1.0 |
| MA position | 1.5 |
| Volume | 3.5 |
- ▸Volume distribution (falling OBV)
- ▸Below 200-MA, MA slope flat
Sentiment
7.1/10data confidence 100%| Component | Sub-score |
|---|---|
| Analyst rating | 7.5 |
| Price target | 9.0 |
| erm sentiment | 4.3 |
- ▸Analyst upside: 36%
Insider
4.0/10data confidence 100%| Component | Sub-score |
|---|---|
| materiality | 3.0 |
| insider conviction | 2.0 |
| holder change | 4.0 |
| notable moves | 7.0 |
- ▸Notable insider selling — $77,751,586 (0.346% of mkt cap)
Peer rank
4.5/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 5.3 |
| quality rank | 4.3 |
| growth rank | 1.6 |
Technical
7.1/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 8.1 |
| support resistance | 9.4 |
| 52w position | 3.8 |
Risk (lower is worse)
5.8/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 8.3 |
| days to cover | 8.5 |
| volatility | 4.3 |
| put call | 0.8 |
| implied vol | 4.2 |
| max pain risk | 5.0 |
| beta | 5.7 |
| debt equity | 9.9 |
- ▸Elevated put/call: 1.89
Catalyst
5.0/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 0.0 |
| earnings timing | 5.0 |
| surprise avg | 10.0 |
- ▸Earnings concerns: 1B/3M
How the verdict was assembled
Engine trigger
Quality below minimum threshold.
Engine technical detail
verdict_path:
L1:HARD_BLOCK:QUALITY_FLOORPassed (7)
- ASYMMETRY:3.5>=1.5
- INSIDER:OK
- 8K:CLEAN
- NEWS_EVENTS:NONE_RECENT
- EARNINGS_PROXIMITY:117d clear
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (2)
- MOMENTUM:3.9<4.5
- DEATH_CROSS:HARD_BLOCK
Warning (0)
none
Reward-to-Risk
3.46
Upside
+22.6%
Downside
6.5%
Sizing output
AVOID
SetupRecovery — Death cross but MACD improving, RSI 46
EdgeNo clear edge — No clear edge identified
SuitabilitySpeculative — Binary industry: Biotechnology
Investment implication
The SELL_IF_HOLDING verdict reflects the MOMENTUM gate's 3.9<4.5 outcome against Sentiment at 7.1 and asymmetric R:R of 3.46.
The strongest dimensions are Sentiment at 7.1, Technical at 7.1, and Value at 6.3; the weakest are Quality at 3.4, Momentum at 3.9, and Insider at 4.0. The V9 engine flagged 2 failed gates, producing an asymmetric reward-to-risk of 3.46 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Analyst Target Upside
Trip ifAnalyst target falls below $95, less than 8% above the current $88.17 price.
- P2Cash Burn Below Quality Floor
Trip ifFree cash flow falls below -20% of revenue from current -9%.
- P3Insider Selling Pressure
Trip ifInsider selling exceeds 1% of market cap over 12 months.
- P4Stalled Momentum Below Trend
Trip ifMomentum score falls below 3.0 from current 4.3.
- P5Low Leverage Balance Sheet
Trip ifDebt-to-equity score falls below 7.0 from current 9.9.